Retention in an antiretroviral therapy programme during an era of decreasing drug cost in Limbe, Cameroon

Journal of the International AIDS Society

Volumn 14, Issue 1, 2011, Pages

  Mosoko, Jembia J ^a,c   Akam, Wilfred ^b   Weidle, Paul J ^c   Brooks, John T ^c   Aweh, Asabi J ^c   Kinge, Thompson N ^b   Pals, Sherri ^c   Raghunathan, Pratima L ^a,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MINISTRY OF PUBLIC HEALTH   (Cameroon)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; INDINAVIR PLUS LAMIVUDINE PLUS STAVUDINE; INDINAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CAMEROON; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PHARMACOECONOMICS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL; ECONOMICS; MIDDLE AGED; PATIENT COMPLIANCE; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CAMEROON; CHILD; CHILD, PRESCHOOL; DRUG COSTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959279681     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-14-32     Document Type: Article

References (25)

1. UNAIDS & WHO, Report on Global HIV/AIDS epidemic Geneva: UNAIDS/WHO 2008 UNAIDS/08.25E/JC1510E.
2. WHO, "3 by 5" progress report 2004 http://www.who.int/3by5/en/ annex1regions.pdf
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. FJ Palella KM Delaney AC Mooman MO Loveless J Fuhrer GA Satten DJ Aschman SD Holmberg, N Engl J Med 1998 338 853 860 10.1056/NEJM199803263381301 9516219 (Pubitemid 28135961)
4. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. G Djomand T Roels T Ellerbrock D Hanson F Diomande B Monga C Maurice J Nkengasong R Konan-Koko A Kadio S Wiktor E Lackritz J Saba T Chorba, AIDS 2003 17 5 S15 14565604
5. Outcomes after providing two years antiretroviral treatment in Khyelitsha, South Africa. D Coetzee K Hilderbrand A Boulle G Maartens F Louis V Labatala H Reuter N Ntwana E Goemaere, AIDS 2004 18 887 895 10.1097/00002030- 200404090-00006 15060436 (Pubitemid 38553709)
6. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine and lamivudine in HIV-1 infected adults in Cameroon; open-label multicentre trial. C Laurent C Kouanfack S Koulla Shiro N Nkoué A Bourgeois A Calmy B Lactuock V Nzeusseu R Mougnutou G Peytavin F Liégeois E Nerrienet M Tardy M Peeters I Andrieux-Meyer L Zekeng M Kazatchkine E Mpoudi-Ngolé E Delaporte, Lancet 2004 364 29 34 10.1016/S0140-6736(04)16586-0 15234853 (Pubitemid 38968622)
7. Long term benefits of highly active antiretroviral therapy in Senegalese HIV-1 infected adults. C Laurent NFN Gneye CT Ndour PM Gueye M Diouf N Diakhaté NC Touré Kane I Lanièce A Ndir L Vergne I Ndoye S Mboup PS Sow Delaporte, J Acquir Immune Defic Syndr 2005 38 14 17 10.1097/00126334-200501010-00003 15608518 (Pubitemid 40094112)
8. Changes in levels of immune activation and reconstitution markers among HIV-1 infected Africans receiving antiretroviral therapy. S Koblavi-Deme M Maran N Kabran MY Borget M Kalou L Kestens C Maurice M Sassan-Morokro ER Ekpini TH Roels T Chorba JN Nkengasong, AIDS 2003 17 17 S22 14565605
9. Antiretroviral therapy in a thousand patients with AIDS in Haiti. P Severe P Leger M Charles F Noel G Bonhomme G Bois E George S Kenel-Pierre PF Wright R Gulick WD Johnson Jr JW Pape DW Fitzgerald, N Engl J Med 2005 353 2325 2334 10.1056/NEJMoa051908 16319381 (Pubitemid 41713744)
10. UNAIDS, 2006 report on the global AIDS epidemic 2006: Treatment and care http://data.unaids.org/pub/GlobalReport/2006/2006-GR-CH07-en.pdf
11. UNAIDS & WHO, Epidemiological fact sheet on HIV and AIDS, Cameroon 2008
12. World Bank the World Bank Group, Data Catalog 2004 http://www.worldbank. org/data/countrydata/countrydata.html
13. Presidency of the Republic of Cameroon: General Information, 2008. http://www.prc.cm/index-en.php?link=b
14. PD Allison, Imputation of Categorical Variables with PROC MI Cary, NC: SAS Institute Inc 2005 Presented at the Thirtieth Annual SAS Users Group International Conference
15. DB Rubin, Multiple Imputation for Nonresponse in Surveys New York: Wiley 1987
16. Out-of-pocket costs of HAART limit HIV treatment responses in Botwana's private sector. GP Bisson I Frank R Gross 3rd Lo Re V JB Strom X Wang M Mogorosi T Gaolathe N Ndwapi H Friedman BL Strom D Dickinson, AIDS 2006 20 1333 6 10.1097/01.aids.0000232245.36039.2b 16816566 (Pubitemid 44030386)
17. Lessons learned from a paying antiretroviral therapy service in the public health sector at Kamuzu Central Hospital, Malawi. MC Hosseinipour FH Neuhann C Kanyama I Mshali S Phakati NL Rezk C van der Horst AD Kashuba, J Int Assoc Physcians AIDS Care 2006 5 103 108 10.1177/1545109706288722
18. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. PJ Weidle S Malamba R Mwebaze, The Lancet 2002 360 34 40 10.1016/S0140-6736(02)09330-3 (Pubitemid 34756490)
19. Association between CD4 cell counts and clinical presentations among HIV/AIDS patients in Cameroon. G Alemnji J Mbuagbaw G Afetane Ml Nkam, J Med Sci 2006 6 843 847 (Pubitemid 44857179)
20. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. DM Moore RS Hogg B Yip E Wood M Tyndall P Braitstein JS Montaner, J Acquir Immune Defic Syndr 2005 40 288 293 10.1097/01.qai.0000182847. 38098.d1 16249702 (Pubitemid 41533068)
21. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. PJ Weidle N Wamai P Solberg C Liechty S Sendagala W Were J Mermin K Buchacz P Behumbiize RL Ransom R Bunnell, The Lancet 2006 368 1587 1594 10.1016/S0140-6736(06)69118-6 (Pubitemid 44767594)
22. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. D Coetzee A Boulle K Hildebrand V Asselman G Van Cutsem E Goemaere, AIDS 2004 18 27 S31 15322481
23. Overview and implementation of an intervention to prevent adherence failure among HIV-infected adults initiating antiretroviral therapy: Lessons learned from Project Heart. G Davies LJ Koenig D Stratford M Palmore T Bush M Golde E Malatino M Todd-Turner TV Ellerbrock, AIDS Care 2006 18 895 903 10.1080/09540120500329556 17012078 (Pubitemid 44521843)
24. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JS Stringer I Zulu J Levy EM Stringer A Mwango BH Chi V Mtonga S Reid RA Cantrell M Bulterys MS Saag RG Marlink A Mwinga TV Ellerbrock M Sinkala, JAMA 2006 296 782 793 10.1001/jama.296.7.782 16905784 (Pubitemid 44223102)
25. Failure to establish HIV Care: Characterizing the "No Show" Phenomenon. MJ Mugavero HY Lin JJ Allison JH Willig PW Chang M Marler JL Raper JE Schumacher M Pisu MS Saag, Clin Infect Dis 2007 45 127 30 10.1086/518587 17554713 (Pubitemid 46984628)